How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Artificial Inseminations Market
- By Technique: Intrauterine Insemination (IUI), Intracervical Insemination (ICI), Intratubal Insemination (ITI), Intravaginal Insemination (IVI)
- By Sperm Source: Partner Sperm, Donor Sperm, Frozen Sperm, Fresh Sperm
- By End User: Human Fertility Clinics, Veterinary Clinics, Livestock Breeding Farms, Research Institutions
- By Animal Type: Cattle, Swine, Equine, Sheep and Goats, Poultry
- By Application: Human Assisted Reproduction, Animal Husbandry and Breeding, Conservation of Endangered Species
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Intrauterine Insemination (IUI) leads By Technique at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 293 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.177 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.185 →
Full report · locked preview
Everything inside the Artificial Inseminations Market report
A complete, evidence-based study - 12 chapters and 123 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Technique 4
Sperm Source 4
End User 4
Animal Type 5
Application 3
Companies profiled
Zoetis Inc.
Genus plc
ABS Global Inc.
Select Sires Inc.
CRV B.V.
Alta Genetics Inc.
Cooperl Arc Atlantique
Vetoquinol S.A.
Neogen Corporation
Elanco Animal Health Incorporated
IMV Technologies
Boehringer Ingelheim Animal Health
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Zoetis Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Genus plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →ABS Global Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Select Sires Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →CRV B.V.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Alta Genetics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Cooperl Arc Atlantique
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Vetoquinol S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Neogen Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Elanco Animal Health Incorporated
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →IMV Technologies
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Boehringer Ingelheim Animal Health
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Minitube of America Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Semex
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →JBS S.A.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,491M by 2033 · 3.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Intrauterine Insemination (IUI)62.7
- Intracervical Insemination (ICI)13.0
- Intratubal Insemination (ITI)9.7
- Intravaginal Insemination (IVI)14.5
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$618.9M → $756.4M · 2.5%
Europe$431.4M → $553.5M · 3.2%
Asia Pacific$393.9M → $493.9M · 2.9%
Latin America$243.8M → $344.1M · 4.4%
Middle East and Africa$187.6M → $262.9M · 4.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →3.562026
3.582027
3.592028
3.612029
3.602030
3.632031
3.632032
3.652033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Zoetis Inc.25.9
- Genus plc16.5
- ABS Global Inc.5.7
- Select Sires Inc.4.7
- CRV B.V.5.4
- Alta Genetics Inc.13.8
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Technique19.2%
Sperm Source26.2%
End User21.2%
Animal Type20.2%
Application13.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.4
- Europe23.0
- Asia Pacific20.5
- Latin America14.3
- Middle East and Africa10.9
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Zoetis Inc. | 90 | 80 | 97 | 87 | 83 | 96 | 89 |
| Genus plc | 77 | 68 | 86 | 74 | 88 | 86 | 80 |
| ABS Global Inc. | 80 | 81 | 71 | 64 | 78 | 63 | 73 |
| Select Sires Inc. | 74 | 58 | 79 | 79 | 65 | 77 | 72 |
| CRV B.V. | 63 | 71 | 61 | 61 | 56 | 66 | 63 |
| Alta Genetics Inc. | 50 | 61 | 50 | 69 | 69 | 60 | 60 |
| Cooperl Arc Atlantique | 63 | 54 | 64 | 52 | 46 | 47 | 54 |
| Vetoquinol S.A. | 40 | 39 | 35 | 41 | 57 | 56 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Zoetis Inc.
- Genus plc
- ABS Global Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Zoetis Inc. | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Genus plc | ◐ | ◐ | ✓ | ◐ | ✓ | ✓ |
| ABS Global Inc. | ✓ | ◐ | ◐ | ◐ | ◐ | − |
| Select Sires Inc. | − | ◐ | ◐ | ✓ | ◐ | ◐ |
| CRV B.V. | − | ✓ | ◐ | ◐ | ◐ | ◐ |
| Alta Genetics Inc. | − | − | ◐ | ✓ | ◐ | ◐ |
| Cooperl Arc Atlantique | ◐ | ◐ | − | ◐ | ◐ | − |
| Vetoquinol S.A. | − | − | − | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Zoetis Inc.89
2Genus plc80
3ABS Global Inc.73
4Select Sires Inc.72
5CRV B.V.63
6Alta Genetics Inc.60
7Cooperl Arc Atlantique54
8Vetoquinol S.A.45
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Zoetis Inc.Genus plc
Challenger2
Strong scale, closing on the leaders.
ABS Global Inc.Select Sires Inc.
Contender2
Focused players with pockets of strength.
CRV B.V.Alta Genetics Inc.
Niche2
Specialists in a single segment or region.
Cooperl Arc AtlantiqueVetoquinol S.A.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Technique in North America, then scale across Artificial Inseminations Market — a $206M beachhead inside a $3.57B market.
Beachhead (SOM)$206Mobtainable near-term
Serviceable (SAM)$1.26Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Intrauterine Insemination (IUI)
Best fit — highest urgency & budget in Technique.
Economic buyer77 fit
Intracervical Insemination (ICI)
Strong fit — clear ROI and a fast path to value.
End user66 fit
Intratubal Insemination (ITI)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Technique in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Sperm Source & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel30%
Digital / self-serve17%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Technique leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Artificial Inseminations Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified46%
Sales qualified25%
Evaluation14%
Closed-won6%
$17.2KCAC
$69KLTV
4.0:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Artificial Inseminations Market is a resilient opportunity — $6.14B by 2033, compounding at 4.8%.
TAM · 2025$4.23Btoday
TAM · 2033$6.14Bforecast
CAGR4.8%2027–2033
Cumulative$46.2Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.14BTotal addressable market
SAM$2.23BServiceable available market
SOM$375MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.8% CAGR
Demand compounds through 2033, outpacing GDP across Technique.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Technique moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.14BLarge & growingTAM by 2033 at 4.8% CAGR
$2.23BServiceable nowreachable with today’s model
$375MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.79BBear3.1% CAGR
$6.14BBase4.8% CAGR
$7.86BBull6.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Sperm Source optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Artificial Inseminations Market — a $6.69B market by 2033. Plan: grow share from 7.4% to 13.2%.
Market size · 2033$6.69Btotal addressable
Market CAGR9.0%2027–2033
Target share13.2%from 7.4% today
Revenue ambition$883Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.4% | 13.2% | Ahead |
| Revenue | $530M | $883M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 29.6% | 45.8% | Ahead |
| Customer retention | 85.5% | 94.4% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Technique
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Sperm Source capability
A defensible second engine — invest in Sperm Source to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Technique share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Sperm Source
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $125M capacity & capability investment
- Greenlight bolt-on M&A in Sperm Source
- Authorise North America expansion plan
- Fund R&D program for Technique leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Artificial Inseminations Market conversation — a $6.39B market you can size, segment and defend in minutes.
Market size · 2033$6.39Btotal opportunity
Growth5.8%CAGR to 2033
Addressable buyers1,753+accounts in scope
Typical ROI6.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Technique
Goal Grow share in Technique
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.3×return on cost, year one
< 4 mopayback period
$82K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Zoetis Inc.Genus plcABS Global Inc.Select Sires Inc.CRV B.V.Alta Genetics Inc.Cooperl Arc AtlantiqueVetoquinol S.A.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Artificial Inseminations Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Artificial Inseminations Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Artificial Intelligence (AI) Chipsets Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportArtificial Intelligence (AI) Governance Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportArtificial Intelligence (AI) Hardware Market
Market size, share, segmentation and regional forecast.
$402M market · 2025 base year
View reportArtificial Intelligence (AI) in Food & Beverages Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportArtificial Intelligence (AI) in Food and Beverage (F&B) Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportArtificial Intelligence (AI) in Hardware Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportArtificial Intelligence (AI) in Hotel Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportArtificial Intelligence (AI) in Media and Entertainment Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportArtificial Intelligence (AI) in Oil and Gas Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportArtificial Intelligence (AI) in Renewable Energy Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportArtificial Intelligence (AI) in Supply Chain Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportArtificial Intelligence (AI) in Ultrasound Imaging Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.